18.44
1.14 (6.59%)
| Penutupan Terdahulu | 17.30 |
| Buka | 17.62 |
| Jumlah Dagangan | 1,654,769 |
| Purata Dagangan (3B) | 983,079 |
| Modal Pasaran | 932,073,664 |
| Harga / Pendapatan (P/E Ke hadapan) | 19.72 |
| Harga / Jualan (P/S) | 583.74 |
| Harga / Buku (P/B) | 48.09 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 24 Mar 2026 |
| EPS Cair (TTM) | -3.69 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.98% |
| Nisbah Semasa (MRQ) | 10.44 |
| Aliran Tunai Operasi (OCF TTM) | -127.65 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -72.82 M |
| Pulangan Atas Aset (ROA TTM) | -58.15% |
| Pulangan Atas Ekuiti (ROE TTM) | -150.50% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | KalVista Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.63 |
|
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.47% |
| % Dimiliki oleh Institusi | 112.39% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Vr Adviser, Llc | 31 Dec 2025 | 6,728,985 |
| Frazier Life Sciences Management, L.P. | 31 Dec 2025 | 5,039,867 |
| Point72 Asset Management, L.P. | 31 Dec 2025 | 2,283,766 |
| Woodline Partners Lp | 31 Dec 2025 | 1,921,092 |
| Vestal Point Capital, Lp | 31 Dec 2025 | 1,890,000 |
| Kynam Capital Management, Lp | 31 Dec 2025 | 1,810,954 |
| Parkman Healthcare Partners Llc | 31 Dec 2025 | 1,768,508 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 37.00 (HC Wainwright & Co., 100.65%) | Beli |
| Median | 36.00 (95.23%) | |
| Rendah | 35.00 (Needham, 89.81%) | Beli |
| Purata | 36.00 (95.23%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 16.80 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 09 Jan 2026 | 37.00 (100.65%) | Beli | 16.80 |
| Needham | 09 Jan 2026 | 35.00 (89.80%) | Beli | 16.80 |
| 06 Jan 2026 | 32.00 (73.54%) | Beli | 15.75 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 03 Feb 2026 | Pengumuman | KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 08 Jan 2026 | Pengumuman | KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results |
| 22 Dec 2025 | Pengumuman | KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |